Streetbeat News

HYPR

Hyperfine, Inc.

https://hyperfine.io

Industry

Medical - Devices

Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.

Open

1.00

Mkt cap

69M

Volume

64K

High

1.00

P/E Ratio

-1.64

52-wk high

1.45

Low

0.94

Div yield

N/A

52-wk low

0.76

Hyperfine presented its advanced imaging data and quality using the Swoop system at the CTAD Conference, focusing on monitoring amyloid-related imaging abnormalities in Alzheimer's research.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 1:03 pm

The SAFE MRI ECMO study, published on September 29, evaluated the use of Hyperfine's ultra-low-field portable MR imaging system on ICU patients undergoing ECMO with a high risk of acute brain injury.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 1:07 pm

Hyperfine's portable Swoop MR imaging system has shown promising interim results in acute stroke care, offering faster scanning times and good specificity compared to conventional MRI.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 1:44 pm

Hyperfine, Inc. (NASDAQ:HYPR) has announced a collaboration with the Medical University of South Carolina to use its Swoop Portable MR Imaging System to assess astronauts' brains before and after the Polaris Dawn mission. This initiative will provide early brain images post-spaceflight.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 12:25 pm

Hyperfine has raised its revenue expectations for FY24 to $13-$16 million, reflecting a year-over-year growth of 31% at the midpoint. The company maintains its cash burn estimate at approximately $40 million for the year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:54 pm

Hyperfine (NASDAQ:HYPR) reported Q2 2024 GAAP EPS of $(0.14), meeting analyst estimates, and sales of $3.631M, beating the $3.263M estimate. This represents a 6.67% improvement in EPS and a 7.39% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:21 pm

Hyperfine, Inc. (NASDAQ:HYPR) presented initial data from observational clinical studies at the 2024 Alzheimer's Association International Conference (AAIC) in Philadelphia. The data highlights the use of their portable MR brain imaging system, Swoop®, in detecting amyloid-related imaging abnormalities (ARIA) in Alzheimer's patients.

Portfolio Pulse from Benzinga Newsdesk

July 30, 2024 | 1:09 pm

Hyperfine (NASDAQ:HYPR) has received FDA clearance for the ninth generation of its AI-powered Swoop® system software, which significantly reduces scan times for brain imaging without compromising quality. This positions Hyperfine as a leader in AI-powered health technology and could expedite diagnostics in acute care settings.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 1:20 pm

Hyperfine's portable MRI system, Swoop®, shows promise in aiding critical stroke treatment decisions, according to a multi-site study published in the August 2024 edition of Annals of Neurology. The study provides early evidence from the ACTION PMR stroke study.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 1:06 pm

Hyperfine, Inc. (NASDAQ:HYPR) will present clinical research on its Swoop® system for Alzheimer's disease monitoring at the 2024 Alzheimer's Association International Conference. The presentations will highlight the utility of portable ultra-low-field MRI in Alzheimer's care.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 1:04 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.